CN116375611A - 一种由脂肪胺合成二氟烷基类化合物的方法 - Google Patents
一种由脂肪胺合成二氟烷基类化合物的方法 Download PDFInfo
- Publication number
- CN116375611A CN116375611A CN202310251612.7A CN202310251612A CN116375611A CN 116375611 A CN116375611 A CN 116375611A CN 202310251612 A CN202310251612 A CN 202310251612A CN 116375611 A CN116375611 A CN 116375611A
- Authority
- CN
- China
- Prior art keywords
- mmol
- reaction
- difluoroalkyl
- cdcl
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 21
- 150000001412 amines Chemical class 0.000 title claims abstract description 14
- 230000002194 synthesizing effect Effects 0.000 title claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 160
- -1 polycyclic aryl Chemical group 0.000 claims abstract description 74
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 64
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 38
- 239000003054 catalyst Substances 0.000 claims abstract description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 7
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000003682 fluorination reaction Methods 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 5
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 4
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 4
- 150000002367 halogens Chemical class 0.000 claims abstract description 4
- 239000007810 chemical reaction solvent Substances 0.000 claims abstract description 3
- 238000005286 illumination Methods 0.000 claims abstract description 3
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims abstract description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 111
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 110
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 36
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 claims description 34
- 150000004056 anthraquinones Chemical group 0.000 claims description 34
- 238000003760 magnetic stirring Methods 0.000 claims description 34
- 239000012046 mixed solvent Substances 0.000 claims description 34
- 239000012363 selectfluor Substances 0.000 claims description 34
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 claims description 33
- 238000003756 stirring Methods 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- RLKHFSNWQCZBDC-UHFFFAOYSA-N n-(benzenesulfonyl)-n-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 claims description 4
- 239000012025 fluorinating agent Substances 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 2
- RZVHIXYEVGDQDX-UHFFFAOYSA-N 9,10-anthraquinone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 RZVHIXYEVGDQDX-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract description 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract description 2
- 150000002148 esters Chemical class 0.000 abstract description 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 2
- 150000005224 alkoxybenzenes Chemical class 0.000 abstract 1
- 150000004996 alkyl benzenes Chemical class 0.000 abstract 1
- 125000005059 halophenyl group Chemical group 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 115
- 238000005481 NMR spectroscopy Methods 0.000 description 96
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 66
- 239000011541 reaction mixture Substances 0.000 description 47
- 238000004587 chromatography analysis Methods 0.000 description 46
- 239000000047 product Substances 0.000 description 35
- 239000012043 crude product Substances 0.000 description 34
- 239000000203 mixture Substances 0.000 description 33
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 32
- 239000007787 solid Substances 0.000 description 28
- 238000001035 drying Methods 0.000 description 27
- 239000012074 organic phase Substances 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 239000008346 aqueous phase Substances 0.000 description 24
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 20
- DTJVECUKADWGMO-UHFFFAOYSA-N 4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1 DTJVECUKADWGMO-UHFFFAOYSA-N 0.000 description 17
- 229920006395 saturated elastomer Polymers 0.000 description 16
- 125000005233 alkylalcohol group Chemical group 0.000 description 15
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 12
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 12
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- MSFQEZBRFPAFEX-UHFFFAOYSA-N 4-methoxybenzenesulfonamide Chemical compound COC1=CC=C(S(N)(=O)=O)C=C1 MSFQEZBRFPAFEX-UHFFFAOYSA-N 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YYZUSRORWSJGET-UHFFFAOYSA-N ethyl octanoate Chemical compound CCCCCCCC(=O)OCC YYZUSRORWSJGET-UHFFFAOYSA-N 0.000 description 6
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 6
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 5
- QTJHNJCILMMRIQ-UHFFFAOYSA-N 1-chloro-6-iodohexane Chemical compound ClCCCCCCI QTJHNJCILMMRIQ-UHFFFAOYSA-N 0.000 description 4
- 150000001348 alkyl chlorides Chemical class 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 3
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 3
- UBTQVPMVWAEGAC-UHFFFAOYSA-N ethyl 8-bromooctanoate Chemical compound CCOC(=O)CCCCCCCBr UBTQVPMVWAEGAC-UHFFFAOYSA-N 0.000 description 3
- MQOBSOSZFYZQOK-UHFFFAOYSA-N fenofibric acid Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C(=O)C1=CC=C(Cl)C=C1 MQOBSOSZFYZQOK-UHFFFAOYSA-N 0.000 description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 3
- 229960003433 thalidomide Drugs 0.000 description 3
- NJWGQARXZDRHCD-UHFFFAOYSA-N 2-methylanthraquinone Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC=C3C(=O)C2=C1 NJWGQARXZDRHCD-UHFFFAOYSA-N 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- WGFOBBZOWHGYQH-MXHNKVEKSA-N lubiprostone Chemical compound O1[C@](C(F)(F)CCCC)(O)CC[C@@H]2[C@@H](CCCCCCC(O)=O)C(=O)C[C@H]21 WGFOBBZOWHGYQH-MXHNKVEKSA-N 0.000 description 2
- 229960000345 lubiprostone Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- AIUKHSIQGFTDMT-UHFFFAOYSA-N 2-[(4-methoxyphenyl)sulfonylamino]benzoic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=CC=C1C(O)=O AIUKHSIQGFTDMT-UHFFFAOYSA-N 0.000 description 1
- WNDXRJBYZOSNQO-UHFFFAOYSA-N 2-methylpentan-1-amine Chemical compound CCCC(C)CN WNDXRJBYZOSNQO-UHFFFAOYSA-N 0.000 description 1
- VJSLUQDJVYXQFG-UHFFFAOYSA-N 4-methoxy-n-(4-phenylbutyl)benzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NCCCCC1=CC=CC=C1 VJSLUQDJVYXQFG-UHFFFAOYSA-N 0.000 description 1
- DZTRTXFIVUJZAU-UHFFFAOYSA-N 4-methyl-n-pentylbenzenesulfonamide Chemical compound CCCCCNS(=O)(=O)C1=CC=C(C)C=C1 DZTRTXFIVUJZAU-UHFFFAOYSA-N 0.000 description 1
- SUTWPJHCRAITLU-UHFFFAOYSA-N 6-aminohexan-1-ol Chemical compound NCCCCCCO SUTWPJHCRAITLU-UHFFFAOYSA-N 0.000 description 1
- RMYDYIDGGSILID-UHFFFAOYSA-N 7-aminoheptanoic acid;hydrochloride Chemical compound Cl.NCCCCCCC(O)=O RMYDYIDGGSILID-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- UUGLJVMIFJNVFH-UHFFFAOYSA-N Benzoesaeure-n-hexylester Natural products CCCCCCOC(=O)C1=CC=CC=C1 UUGLJVMIFJNVFH-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 101000960235 Dictyostelium discoideum Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 1
- 101100391174 Dictyostelium discoideum forC gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003467 chloride channel stimulating agent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- LTVOKYUPTHZZQH-UHFFFAOYSA-N difluoromethane Chemical group F[C]F LTVOKYUPTHZZQH-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960000701 fenofibric acid Drugs 0.000 description 1
- 238000004334 fluoridation Methods 0.000 description 1
- 239000002920 hazardous waste Substances 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 150000002384 heptanoic acid esters Chemical class 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
- WIJZXSAJMHAVGX-DHLKQENFSA-N ivosidenib Chemical compound FC1=CN=CC(N([C@H](C(=O)NC2CC(F)(F)C2)C=2C(=CC=CC=2)Cl)C(=O)[C@H]2N(C(=O)CC2)C=2N=CC=C(C=2)C#N)=C1 WIJZXSAJMHAVGX-DHLKQENFSA-N 0.000 description 1
- 229950010738 ivosidenib Drugs 0.000 description 1
- 150000004658 ketimines Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- PRKPASPTOKZCDJ-UHFFFAOYSA-N n-heptyl-4-methoxybenzenesulfonamide Chemical compound CCCCCCCNS(=O)(=O)C1=CC=C(OC)C=C1 PRKPASPTOKZCDJ-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
- C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/04—Preparation
- C07D499/08—Modification of a carboxyl radical directly attached in position 2, e.g. esterification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/86—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with only atoms other than nitrogen atoms directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02B—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO BUILDINGS, e.g. HOUSING, HOUSE APPLIANCES OR RELATED END-USER APPLICATIONS
- Y02B20/00—Energy efficient lighting technologies, e.g. halogen lamps or gas discharge lamps
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
技术领域
本发明属于有机合成技术领域,具体涉及一种由脂肪胺合成二氟烷基类化合物的方法。
背景技术
二氟烷基化合物在制药、农用化学品和材料科学中具有非常重要的应用。将二氟亚甲基(CF2)基团选择性地引入有机分子可以显着提高生物活性分子的代谢稳定性和口服生物利用度,是有机合成和药物化学中的重要结构。例如鲁比前列酮(Lubiprostone)为局限性氯离子通道激活剂,用于治疗成人慢性特发性便秘。艾伏尼布(Ivosidenib),一种针对异柠檬酸脱氢酶-1(IDH1)突变癌症的强效口服靶向抑制剂。
二氟烷基化合物具有重要的药用价值,因此,合成含有该基团的化合物的有效策略受到了广泛关注。在各种策略中,通过直接二氟化形成多样化分子和后期功能化复杂底物尤其可取,因为它可以避免预功能化并减少危险废物的产生,但是直接的二氟化的高效策略却很少。例如,Kimpe课题组(Org.Lett.2006,8(21),4767-4770)利用NFSI(N-氟代双苯磺酰胺)作为氟化试剂的方法,直接实现了酮亚胺αC(sp3)-H键的氟化和二氟化反应。2014年Lectka课题组(J.Org.Chem.2014,79(20),9830-9834)介绍了一种利用1,8-萘啶作为螯合亲核试剂以及Selectfluor(1-氯甲基-4-氟-1,4-二氮杂双环[2.2.2]辛烷二(四氟硼酸)盐)作为氟源的方法,实现了酰氯的α,α-二氟化反应。2019年Britton课题组(Chem.Sci.2018,9(25),5608-5613)利用碳酸锂和NFSI作为氟源,直接在杂环化合物上引入双氟烷基,实现了杂苄基C(sp3)–H的二氟化。然而,由于C(sp3)-H键的高惰性和低活性,实现脂肪族烷基链上的连续二氟化仍是一个难题,目前尚无相关报道。因此,开发一种经济、高效、温和的策略实现高效构建二氟烷基类化合物具有重要的意义。
发明内容
针对现有技术中存在的上述问题,本发明的目的是提供一种高效、环境友好的由脂肪胺合成二氟烷基类化合物的方法。
本发明的技术方案具体介绍如下。
本发明限定了一种由脂肪胺合成二氟烷基类化合物的方法,具体为:在氮气保护下,将式(Ⅰ)所示的脂肪胺、氟化试剂和催化剂加入到溶剂中,光照下进行搅拌反应,反应结束后经分离、提纯得到式(Ⅱ)所示的二氟烷基化合物,其反应方程式如下:
式(Ⅰ)中,R1选自苯磺酰基及其衍生物;R2、R3选自烷基、烷氧基、环烷基、酯基、苯基、苄基、取代苯基、多环芳基、杂环基、卤素,取代苯基中的取代基为烷基、烷氧基或卤素;
进一步地,本发明还限定了氟化试剂为Selectfluor(1-氯甲基-4-氟-1,4-二氮杂双环[2.2.2]辛烷二(四氟硼酸)盐)或NFSI(N-氟代双苯磺酰胺)。
进一步地,本发明还限定了催化剂为蒽醌或蒽醌衍生物。
进一步地,本发明还限定了光源为白光、蓝光或紫光。
进一步地,本发明还限定了式(Ⅰ)所示的脂肪胺、氟化试剂、催化剂的物质的量比为1:2.0~5.0:0.001~0.1,优选摩尔比为1:2.5~3.5:0.01~0.05。
进一步地,本发明还限定了反应温度为0-50℃,优选为25-35℃。
进一步地,本发明还限定了反应时间为0.5~10h,优选为1.5-3.5h。
进一步地,本发明还限定了溶剂为A溶剂与B溶剂的混合溶剂,A溶剂选自2,2,2-三氟乙醇或1,1,1,3,3,3-六氟-2-丙醇,B溶剂选自乙腈、乙酸乙酯、二甲基亚砜或二氯甲烷中的一种,A溶剂与B溶剂的投料体积比0.1~1.0:1,优选为0.4-0.6:1。
进一步地,本发明还限定了分离、提纯的具体处理过程为:反应液减压浓缩后经色谱柱分离纯化,得到式(Ⅱ)所示的二氟烷基化合物。
进一步地,本发明还限定了具体的方法为:在装有磁力搅拌的反应管中加入式(Ⅰ)所示的脂肪胺、氟化试剂、催化剂和反应溶剂,氮气置换后,将反应体系置于光源照射下,于0-50℃下搅拌反应0.5~10h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到式(Ⅱ)所示的目标化合物二氟烷基类化合物。
通过采用上述技术,本发明的有益效果在于:本发明以易得的脂肪胺类化合物为起始原料,使用了廉价的催化剂以及安全的氟化试剂高效地合成二氟烷基类化合物,具有操作简单、反应条件温和,后处理简单等优点,为药物的合成与修饰提供一种新方法。
具体实施方式
以下结合实施例对本发明作进一步的描述,但本发明的保护范围并不仅限于此:
实施例1 N-(4,4-二氟戊基)苯磺酰胺
在装有磁力搅拌的反应管中加入N-戊基-4-甲氧基苯磺酰胺(51.5mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率85%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.79(d,J=8.9Hz,2H),6.97(d,J=9.0Hz,2H),4.89(s,1H),3.86(s,3H),2.95(q,J=6.7Hz,2H),1.84(tt,J=16.0,7.9Hz,2H),1.65(p,J=7.0Hz,2H),1.53(t,J=18.3Hz,3H).
13C NMR(101MHz,CDCl3)δ162.94,131.41,129.16,123.88(t,J=238.0Hz),114.32,55.62,42.63,34.87(t,J=25.8Hz),23.39(t,J=27.9Hz),22.94(t,J=4.4Hz).
19F NMR(376MHz,CDCl3)δ-91.10.
实施例2 N-(4,4-二氟戊基)-4-甲基苯磺酰胺
在装有磁力搅拌的反应管中加入N-戊基-4-甲基苯磺酰胺(48.3mg,0.2mmol),NFSI(189.2mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率53%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.75(d,J=8.9Hz,2H),7.31(d,J=8.9Hz,2H),4.93(s,1H),3.00–2.92(m,2H),2.42(s,3H),2.06–1.88(m,2H),1.81–1.71(m,2H),1.61(t,J=18.5Hz,3H).
13C NMR(100MHz,CDCl3)δ142.91,136.23,129.79,128.28(t,J=238.1Hz),127.21,43.75,35.48(t,J=25.2Hz),23.71(t,J=27.3Hz),23.24(t,J=4.9Hz),22.27.
19F NMR(376MHz,CDCl3)δ-91.35.
实施例3 N-(4,4-二氟己基)-4-甲氧基苯磺酰胺
在装有磁力搅拌的反应管中加入N-已基-4-甲氧基苯磺酰胺(54.3mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),2-甲基蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率80%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.79(d,J=8.9Hz,2H),6.97(d,J=8.9Hz,2H),4.86(s,1H),3.86(s,3H),2.96(q,J=6.7Hz,2H),1.90–1.54(m,6H),0.95(t,J=7.6Hz,3H).
13C NMR(101MHz,CDCl3)δ162.93,131.45,129.17,125.07(t,J=240.5Hz),114.31,55.61,42.73,32.85(t,J=25.9Hz),29.73(t,J=26.2Hz),22.56,6.53.
19F NMR(376MHz,CDCl3)δ-100.56.
HRMS:Calcd forC13H20F2NO3S+[M+H]+:308.1126,found:
实施例4 N-(4,4-二氟庚基)-4-甲氧基苯磺酰胺
在装有磁力搅拌的反应管中加入N-庚基-4-甲氧基苯磺酰胺(57.1mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙酸乙酯与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率59%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.79(d,J=8.2Hz,2H),6.97(d,J=8.1Hz,2H),4.87(s,1H),3.86(s,3H),3.04–2.88(m,2H),1.95–1.55(m,6H),1.50–1.36(m,2H),0.92(t,J=7.3Hz,3H).
13C NMR(101MHz,CDCl3)δ162.94,131.39,129.19,124.85(t,J=240.5Hz),114.32,55.63,42.73,38.62(t,J=25.0Hz),33.24(t,J=25.9Hz),22.57(t,J=4.4Hz),15.75(t,J=5.0Hz),13.89.
19F NMR(376MHz,CDCl3)δ-98.33.
实施例5 N-(4,4-二氟辛基)-4-甲氧基苯磺酰胺
在装有磁力搅拌的反应管中加入N-辛基-4-甲氧基苯磺酰胺(57.1mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的二甲基亚砜与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率68%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.79(d,J=8.9Hz,2H),6.97(d,J=8.9Hz,2H),4.84(t,J=6.5Hz,1H),3.86(s,3H),2.96(q,J=6.7Hz,2H),1.89–1.57(m,6H),1.47–1.20(m,4H),0.89(t,J=7.1Hz,3H).
13C NMR(101MHz,CDCl3)δ162.93,131.47,129.17,124.92(t,J=240.5Hz),114.30,55.60,42.73,36.29(t,J=25.2Hz),33.26(t,J=25.9Hz),24.34,22.60,22.42,13.78.
19F NMR(376MHz,CDCl3)δ-98.34.
实施例6 N-(4,4-二氟十八烷基)-4-甲氧基苯磺酰胺
在0℃下将十八胺(5.0mmol,1.3g)和三乙胺(5.5mmol,0.56g)溶解在DCM(25mL)中。在5分钟内缓慢加入对甲氧基苯磺酰氯(5mmol,1.0g)的DCM溶液(5mL)。滴加完成后,使混合物升温至室温并将溶液搅拌24h。用水(5mL)和1.0M HCl(11mL)淬灭反应液。水相用10mL*3DCM萃取。合并的有机相用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化,得到白色固体的N-十八烷基-4-甲氧基苯磺酰胺,收率79%。
在装有磁力搅拌的反应管中加入N-十八烷基-4-甲氧基苯磺酰胺(87.9mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的二氯甲烷与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率53%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.79(d,J=8.9Hz,2H),6.98(d,J=8.8Hz,2H),4.65(s,1H),3.87(s,3H),2.97(q,J=6.7Hz,2H),1.91–1.56(m,6H),1.45–1.35(m,2H),1.34–1.16(m,23H),0.87(t,J=6.8Hz,3H).
13C NMR(101MHz,CDCl3)δ162.96,131.56,129.18,124.89(t,J=240.7Hz),114.31,55.60,42.74,36.64(t,J=25.2Hz),33.27(t,J=25.9Hz),29.67,29.66,29.63,29.59,29.55,29.47,29.36,29.35,29.33,22.63(t,J=4.0Hz),22.27(t,J=4.6Hz),14.07.
19F NMR(376MHz,CDCl3)δ-98.41.
实施例7(S)-5,5-二氟-2-((4-甲氧基苯基)磺酰氨基)己酸甲酯
将L-正亮氨酸(10mmol,1.3g)加入100mL甲醇中并在0℃下冷却。加入二氯亚砜(30mmol,3.6g),使混合物升温至室温并将溶液搅拌12h。减压浓缩溶液以获得粗胺盐酸盐。在0℃下将粗胺盐酸盐和三乙胺(30mmol,0.3g)溶解在50mLDCM中。在5分钟内缓慢加入对甲氧基苯磺酰氯(10mmol,2.1g)的DCM溶液(20mL)。添加完成后,使混合物升温至室温并将溶液搅拌12h。用水(10mL)和1.0M HCl(10mL)淬灭反应混合物。水相用20mL*3DCM萃取,合并的有机相用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化,得到白色固体的(S)-2-((4-甲氧基苯基)磺酰氨基)己酸甲酯,收率37%。
在装有磁力搅拌的反应管中加入(S)-2-((4-甲氧基苯基)磺酰氨基)己酸甲酯(63.1mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与1,1,1,3,3,3-六氟-2-丙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率71%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.76(d,J=8.9Hz,2H),6.96(d,J=8.9Hz,2H),5.22(s,1H),3.93–3.87(m,1H),3.86(s,3H),3.53(s,3H),2.06–1.72(m,4H),1.57(t,J=18.4Hz,3H).
13C NMR(101MHz,CDCl3)δ171.70,163.16,130.98,129.43,123.46(t,J=238.3Hz),114.24,55.64,55.18,52.72,33.64(t,J=25.9Hz),26.39(t,J=4.6Hz),23.56(t,J=27.8Hz).
19F NMR(376MHz,CDCl3)δ-91.96.
实施例8 3,3-二氟-6-((4-甲氧基苯基)磺酰氨基)己基4-甲氧基苯磺酸盐
在0℃下将6-氨基-1-已醇(2.0mmol,234mg)和三乙胺(6mmol,607mg)溶解在10mLDCM中。在5分钟内缓慢加入对甲氧基苯磺酰氯(6mmol,1.2g)的DCM溶液(10mL)。添加完成后,使混合物升温至室温并搅拌12h。用水(3mL)和1.0M HCl(6mL)淬灭反应混合物。水相用DCM萃取,合并的有机相用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化,得到白色固体的6-((4-甲氧基苯基)磺酰氨基)己基4-甲氧基苯磺酸盐,收率71%。
在装有磁力搅拌的反应管中加入6-((4-甲氧基苯基)磺酰氨基)己基4-甲氧基苯磺酸盐(91.5mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为10:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率59%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.85(d,J=9.0Hz,2H),7.79(d,J=9.0Hz,2H),7.03(d,J=9.0Hz,2H),6.98(d,J=9.0Hz,2H),4.68(brs,1H),4.15(t,J=6.5Hz,2H),3.89(s,3H),3.87(s,3H),2.95(t,J=6.7Hz,2H),2.20(tt,J=15.6,6.5Hz,2H),1.94–1.78(m,2H),1.69–1.59(m,2H).
13C NMR(101MHz,CDCl3)δ164.05,162.97,131.31,130.22,129.21,126.72,123.20(t,J=241.5Hz),114.67,114.36,63.97(t,J=6.1Hz),55.80,55.67,42.48,35.92(t,J=26.0Hz),33.63(t,J=25.3Hz),22.40(t,J=4.3Hz).
19F NMR(376MHz,CDCl3)δ-97.26.
实施例9 N-(6-(3-(1,3-二氧代异吲哚啉-2-基)-2,6-二氧代哌啶-1-基)-4,4-二氟己基)-4-甲氧基苯磺酰胺
向25mL Schlenk烧瓶中加入沙利度胺(3mmol,774mg)、1-氯-6-碘己烷(4.5mmol,1.0g)、碳酸钾(4.5mmol,747mg)和15mL乙腈。将反应混合物加热至回流24h。减压浓缩反应混合物。通过色谱法纯化粗产物,得到无色油状液体。将得到的烷基氯(2.0mmol,726mg)、对甲氧基苯磺酰胺(4.0mmol,749mg)、碳酸钾(4.0mmol,553mg)和碘化钾(4.0mmol,332mg)加入装有8mL DMF的圆底烧瓶。然后将反应混合物加热至90℃并保持24h。冷却至室温后,将反应混合物用100mL水稀释并用10mL*3DCM萃取。合并的有机相用饱和盐水洗涤并用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化,得到白色固体的N-(6-(3-(1,3-二氧异吲哚-2-基)-2,6-二氧哌啶-1-基)己基)-4-甲氧基苯磺酰胺,产率43%。
在装有磁力搅拌的反应管中加入N-(6-(3-(1,3-二氧异吲哚-2-基)-2,6-二氧哌啶-1-基)己基)-4-甲氧基苯磺酰胺(105.5mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为1:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率63%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.92–7.83(m,2H),7.83–7.71(m,4H),6.95(d,J=8.4Hz,2H),5.06–4.95(m,1H),4.81(s,1H),4.06–3.89(m,2H),3.84(s,3H),3.05–2.89(m,3H),2.86–2.67(m,2H),2.16–1.98(m,3H),1.91–1.77(m,2H),1.70–1.57(m,2H).
13C NMR(101MHz,CDCl3)δ170.78,168.51,167.46,162.87,134.55,131.69,131.48,129.18,123.85(t,J=242.5Hz),123.83,114.29,55.63,50.07,42.53,34.59(t,J=6.1Hz),34.09(t,J=25.3Hz),33.17(t,J=25.2Hz),31.88,22.43(t,J=4.1Hz),21.94.
19F NMR(376MHz,CDCl3)δ-98.13.
实施例10 N-(6-(3-(1,3-二氧代异吲哚啉-2-基)-2,6-二氧代哌啶-1-基)-4,4-二氟己基)-4-甲氧基苯磺酰胺
向25mL Schlenk烧瓶中加入沙利度胺(3mmol,774mg)、1-氯-6-碘己烷(4.5mmol,1.0g)、碳酸钾(4.5mmol,747mg)和15mL乙腈。将反应混合物加热至回流24h。减压浓缩反应混合物。通过色谱法纯化粗产物,得到无色油状液体。将得到的烷基氯(2.0mmol,726mg)、对甲氧基苯磺酰胺(4.0mmol,749mg)、碳酸钾(4.0mmol,553mg)和碘化钾(4.0mmol,332mg)加入装有8mL DMF的圆底烧瓶。然后将反应混合物加热至90℃并保持24h。冷却至室温后,将反应混合物用100mL水稀释并用10mL*3DCM萃取。合并的有机相用饱和盐水洗涤并用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化,得到白色固体的N-(6-(3-(1,3-二氧异吲哚-2-基)-2,6-二氧哌啶-1-基)己基)-4-甲氧基苯磺酰胺,产率43%。
在装有磁力搅拌的反应管中加入N-(6-(3-(1,3-二氧异吲哚-2-基)-2,6-二氧哌啶-1-基)己基)-4-甲氧基苯磺酰胺(105.5mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:5的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率75%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.92–7.83(m,2H),7.83–7.71(m,4H),6.95(d,J=8.4Hz,2H),5.06–4.95(m,1H),4.81(s,1H),4.06–3.89(m,2H),3.84(s,3H),3.05–2.89(m,3H),2.86–2.67(m,2H),2.16–1.98(m,3H),1.91–1.77(m,2H),1.70–1.57(m,2H).
13C NMR(101MHz,CDCl3)δ170.78,168.51,167.46,162.87,134.55,131.69,131.48,129.18,123.85(t,J=242.5Hz),123.83,114.29,55.63,50.07,42.53,34.59(t,J=6.1Hz),34.09(t,J=25.3Hz),33.17(t,J=25.2Hz),31.88,22.43(t,J=4.1Hz),21.94.
19F NMR(376MHz,CDCl3)δ-98.13.
实施例11 N-(6-(3-(1,3-二氧代异吲哚啉-2-基)-2,6-二氧代哌啶-1-基)-4,4-二氟己基)-4-甲氧基苯磺酰胺
向25mL Schlenk烧瓶中加入沙利度胺(3mmol,774mg)、1-氯-6-碘己烷(4.5mmol,1.0g)、碳酸钾(4.5mmol,747mg)和15mL乙腈。将反应混合物加热至回流24h。减压浓缩反应混合物。通过色谱法纯化粗产物,得到无色油状液体。将得到的烷基氯(2.0mmol,726mg)、对甲氧基苯磺酰胺(4.0mmol,749mg)、碳酸钾(4.0mmol,553mg)和碘化钾(4.0mmol,332mg)加入装有8mL DMF的圆底烧瓶。然后将反应混合物加热至90℃并保持24h。冷却至室温后,将反应混合物用100mL水稀释并用10mL*3DCM萃取。合并的有机相用饱和盐水洗涤并用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化,得到白色固体的N-(6-(3-(1,3-二氧异吲哚-2-基)-2,6-二氧哌啶-1-基)己基)-4-甲氧基苯磺酰胺,产率43%。
在装有磁力搅拌的反应管中加入N-(6-(3-(1,3-二氧异吲哚-2-基)-2,6-二氧哌啶-1-基)己基)-4-甲氧基苯磺酰胺(105.5mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为3:5的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率71%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.92–7.83(m,2H),7.83–7.71(m,4H),6.95(d,J=8.4Hz,2H),5.06–4.95(m,1H),4.81(s,1H),4.06–3.89(m,2H),3.84(s,3H),3.05–2.89(m,3H),2.86–2.67(m,2H),2.16–1.98(m,3H),1.91–1.77(m,2H),1.70–1.57(m,2H).
13C NMR(101MHz,CDCl3)δ170.78,168.51,167.46,162.87,134.55,131.69,131.48,129.18,123.85(t,J=242.5Hz),123.83,114.29,55.63,50.07,42.53,34.59(t,J=6.1Hz),34.09(t,J=25.3Hz),33.17(t,J=25.2Hz),31.88,22.43(t,J=4.1Hz),21.94.
19F NMR(376MHz,CDCl3)δ-98.13.
实施例12 N-(5,5-二氟己-2-基)-4-甲氧基苯磺酰胺
在装有磁力搅拌的反应管中加入N-(己-2-基)-4-甲氧基苯磺酰胺(54.3mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的白光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率77%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.81(d,J=8.9Hz,2H),6.97(d,J=8.9Hz,2H),4.56(brs,1H),3.87(s,3H),3.38–3.22(m,1H),1.95–1.47(m,7H),1.07–0.93(m,3H).
13C NMR(101MHz,CDCl3)δ162.89,132.68,129.11,123.90(t,J=238.0Hz),114.27,55.61,49.62,34.19(t,J=25.7Hz),30.33(t,J=4.3Hz),23.45(t,J=27.9Hz),21.63.
19F NMR(376MHz,CDCl3)δ-91.35.
实施例13 N-(4,4-二氟-2-甲基戊基)-4-甲氧基苯磺酰胺
在0℃下将2-甲基戊-1-胺(5.0mmol,506mg)和三乙胺(5.5mmol,0.56g)溶解在DCM(25mL)中。在5分钟内缓慢加入对甲氧基苯磺酰氯(5mmol,1.0g)的DCM溶液(5mL)。滴加完成后,使混合物升温至室温并将溶液搅拌24h。用水(5mL)和1.0M HCl(11mL)淬灭反应液。水相用10mL*3DCM萃取。合并的有机相用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化,得到淡黄色固体的N-(2-甲基戊基)-4-甲氧基苯磺酰胺,收率96%。
在装有磁力搅拌的反应管中加入N-(2-甲基戊基)-4-甲氧基苯磺酰胺(54.3mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的紫光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率68%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.78(d,J=8.9Hz,2H),6.97(d,J=8.9Hz,2H),4.96(s,1H),3.85(d,J=0.9Hz,3H),2.93–2.69(m,2H),2.02–1.84(m,2H),1.74–1.60(m,1H),1.54(t,J=18.6Hz,3H),0.97(d,J=6.4Hz,3H).
13C NMR(101MHz,CDCl3)δ162.89,131.53,129.13,124.23(t,J=238.4Hz),114.29,55.61,48.88,41.46(t,J=24.6Hz),28.62(t,J=3.1Hz),24.04(t,J=27.9Hz),18.53.
19F NMR(376MHz,CDCl3)δ-88.79(dd,J=353.1,239.9Hz).
实施例14 N-(4,4-二氟-4-苯基丁基)-4-甲氧基苯磺酰胺
在装有磁力搅拌的反应管中加入4-甲氧基-N-(4-苯基丁基)苯磺酰胺(63.9mg,0.2mmol),Selectfluor(141.7mg,0.4mmol),蒽醌(2.1mg,0.01mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率42%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.77(d,J=8.9Hz,2H),7.45–7.36(m,5H),6.95(d,J=8.9Hz,2H),4.80(t,J=6.4Hz,1H),3.85(s,3H),2.95(q,J=6.7Hz,2H),2.22–2.02(m,2H),1.69–1.56(m,2H).
13C NMR(101MHz,CDCl3)δ162.94,136.94(t,J=26.5Hz),131.45,129.78,129.15,128.46,124.80(t,J=6.3Hz),122.63(t,J=242.5Hz),114.31,55.61,42.57,36.07(t,J=28.1Hz),22.94.
19F NMR(376MHz,CDCl3)δ-95.73.
实施例15 5,5-二氟-8-((4-甲氧基苯基)磺酰氨基)辛酸乙酯
将8-溴辛酸乙酯(2.0mmol,502mg)、对甲氧基苯磺酰胺(4.0mmol,749mg)和碳酸钾(4.0mmol,553mg)加入装有10mL乙腈的圆底烧瓶中。然后将反应混合物加热至回流12h。冷却至室温后,将反应混合物减压浓缩。将5mL乙酸乙酯加入到残余物中并滤出不溶物。减压浓缩溶液,通过色谱法纯化产物,以得到无色油状的8-((4-甲氧基苯基)磺酰氨基)辛酸乙酯,收率93%。
在装有磁力搅拌的反应管中加入8-((4-甲氧基苯基)磺酰氨基)辛酸乙酯(71.5mg,0.2mmol),Selectfluor(354.3mg,1.0mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率68%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.79(d,J=8.5Hz,2H),6.97(d,J=8.4Hz,2H),4.73(s,1H),4.12(q,J=6.8Hz,2H),3.86(s,3H),2.96(t,J=7.0Hz,2H),2.33(t,J=6.8Hz,2H),1.93–1.50(m,8H),1.25(t,J=7.0Hz,3H).
13C NMR(101MHz,CDCl3)δ173.02,162.93,131.39,129.19,124.53(t,J=240.8Hz),114.31,60.49,55.64,42.65,35.73(t,J=25.5Hz),33.52,33.27(t,J=25.8Hz),22.53(t,J=4.3Hz),17.77(t,J=4.9Hz),14.23.
19F NMR(376MHz,CDCl3)δ-98.71.
实施例16 5,5-二氟-8-((4-甲氧基苯基)磺酰氨基)辛酸乙酯
将8-溴辛酸乙酯(2.0mmol,502mg)、对甲氧基苯磺酰胺(4.0mmol,749mg)和碳酸钾(4.0mmol,553mg)加入装有10mL乙腈的圆底烧瓶中。然后将反应混合物加热至回流12h。冷却至室温后,将反应混合物减压浓缩。将5mL乙酸乙酯加入到残余物中并滤出不溶物。减压浓缩溶液,通过色谱法纯化产物,以得到无色油状的8-((4-甲氧基苯基)磺酰氨基)辛酸乙酯,收率93%。
在装有磁力搅拌的反应管中加入8-((4-甲氧基苯基)磺酰氨基)辛酸乙酯(71.5mg,0.2mmol),Selectfluor(177.2mg,0.5mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率76%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.79(d,J=8.5Hz,2H),6.97(d,J=8.4Hz,2H),4.73(s,1H),4.12(q,J=6.8Hz,2H),3.86(s,3H),2.96(t,J=7.0Hz,2H),2.33(t,J=6.8Hz,2H),1.93–1.50(m,8H),1.25(t,J=7.0Hz,3H).
13C NMR(101MHz,CDCl3)δ173.02,162.93,131.39,129.19,124.53(t,J=240.8Hz),114.31,60.49,55.64,42.65,35.73(t,J=25.5Hz),33.52,33.27(t,J=25.8Hz),22.53(t,J=4.3Hz),17.77(t,J=4.9Hz),14.23.
19F NMR(376MHz,CDCl3)δ-98.71.
实施例17 5,5-二氟-8-((4-甲氧基苯基)磺酰氨基)辛酸乙酯
将8-溴辛酸乙酯(2.0mmol,502mg)、对甲氧基苯磺酰胺(4.0mmol,749mg)和碳酸钾(4.0mmol,553mg)加入装有10mL乙腈的圆底烧瓶中。然后将反应混合物加热至回流12h。冷却至室温后,将反应混合物减压浓缩。将5mL乙酸乙酯加入到残余物中并滤出不溶物。减压浓缩溶液,通过色谱法纯化产物,以得到无色油状的8-((4-甲氧基苯基)磺酰氨基)辛酸乙酯,收率93%。
在装有磁力搅拌的反应管中加入8-((4-甲氧基苯基)磺酰氨基)辛酸乙酯(71.5mg,0.2mmol),Selectfluor(248.0mg,0.7mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率68%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.79(d,J=8.5Hz,2H),6.97(d,J=8.4Hz,2H),4.73(s,1H),4.12(q,J=6.8Hz,2H),3.86(s,3H),2.96(t,J=7.0Hz,2H),2.33(t,J=6.8Hz,2H),1.93–1.50(m,8H),1.25(t,J=7.0Hz,3H).
13C NMR(101MHz,CDCl3)δ173.02,162.93,131.39,129.19,124.53(t,J=240.8Hz),114.31,60.49,55.64,42.65,35.73(t,J=25.5Hz),33.52,33.27(t,J=25.8Hz),22.53(t,J=4.3Hz),17.77(t,J=4.9Hz),14.23.
19F NMR(376MHz,CDCl3)δ-98.71.
实施例18 3,3-二氟-6-((4-甲氧基苯基)磺酰氨基)苯甲酸己酯
在0℃下将6-氨基己-1-醇(2.0mmol,234mg)和三乙胺(2.2mmol,222mg)溶解在25mLDCM中。在5分钟内缓慢加入对甲氧基苯磺酰氯(2.2mmol,455mg)的DCM溶液(5mL)。滴加完成后,使混合物升温至室温并将溶液搅拌12h。用水(5mL)和饱和NaHCO3溶液(5mL)淬灭反应混合物。水相用10mL*3DCM萃取。合并的有机相用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化得到白色固体。在0℃下将得到的烷基醇(2.0mmol,574mg)和三乙胺(2.2mmol,222mg)溶解在25mLDCM中。在5分钟内缓慢加入苯甲酰氯(2.2mmol,309mg)的DCM溶液(5mL)。滴加完成后,使混合物升温至室温并将溶液搅拌12h。用水(5mL)和饱和NaHCO3溶液(5mL)淬灭反应混合物。水相用10mL*3DCM萃取。合并的有机相用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化,得到白色固体的6-((4-甲氧基苯基)磺酰氨基)苯甲酸己酯,收率86%。
在装有磁力搅拌的反应管中加入6-((4-甲氧基苯基)磺酰氨基)苯甲酸己酯(78.3mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.04mg,0.0002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率36%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ8.02(d,J=6.9Hz,2H),7.78(d,J=8.9Hz,2H),7.57(t,J=7.5Hz,1H),7.45(t,J=7.8Hz,2H),6.96(d,J=8.9Hz,2H),4.72(s,1H),4.47(t,J=6.6Hz,2H),3.85(s,3H),2.98(t,J=5.8Hz,2H),2.29(tt,J=16.0,6.5Hz,2H),2.04–1.86(m,2H),1.78–1.64(m,2H).
13C NMR(101MHz,CDCl3)δ166.33,162.95,133.16,131.44,129.85,129.58,129.16,128.48,123.57(t,J=241.5Hz),114.32,58.84(t,J=6.0Hz),55.61,42.61,35.85(t,J=25.6Hz),33.77(t,J=25.3Hz),22.51(t,J=4.4Hz).
19F NMR(376MHz,CDCl3)δ-97.82.
实施例19 3,3-二氟-6-((4-甲氧基苯基)磺酰氨基)己基4-氟苯甲酸酯
在0℃下将6-氨基己-1-醇(2.0mmol,234mg)和三乙胺(2.2mmol,222mg)溶解在25mLDCM中。在5分钟内缓慢加入对甲氧基苯磺酰氯(2.2mmol,455mg)的DCM溶液(5mL)。滴加完成后,使混合物升温至室温并将溶液搅拌12h。用水(5mL)和饱和NaHCO3溶液(5mL)淬灭反应混合物。水相用10mL*3DCM萃取。合并的有机相用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化得到白色固体。在0℃下将得到的烷基醇(2.0mmol,574mg)和三乙胺(2.2mmol,222mg)溶解在25mLDCM中。在5分钟内缓慢加入对氟苯甲酰氯(2.2mmol,349mg)的DCM溶液(5mL)。滴加完成后,使混合物升温至室温并将溶液搅拌12h。用水(5mL)和饱和NaHCO3溶液(5mL)淬灭反应混合物。水相用10mL*3DCM萃取。合并的有机相用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化,得到白色固体的6-((4-甲氧基苯基)磺酰氨基)己基4-氟苯甲酸酯,收率97%。
在装有磁力搅拌的反应管中加入6-((4-甲氧基苯基)磺酰氨基)己基4-氟苯甲酸酯(81.9mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(4.2mg,0.02mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率58%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ8.05–7.99(m,2H),7.77(d,J=8.9Hz,2H),7.14–7.06(m,2H),6.95(d,J=8.9Hz,2H),5.02(s,1H),4.45(t,J=6.5Hz,2H),3.84(s,3H),2.96(q,J=6.3Hz,2H),2.27(tt,J=16.1,6.5Hz,2H),2.02–1.85(m,2H),1.76–1.63(m,2H).
13C NMR(101MHz,CDCl3)δ165.88(d,J=254.2Hz),165.38,162.97,132.17(d,J=9.4Hz),131.47,129.14,126.14(d,J=3.0Hz),123.58(t,J=241.6Hz),115.62(d,J=22.0Hz),114.33,58.95(t,J=5.8Hz),55.59,42.59,35.80(t,J=25.6Hz),33.81(t,J=25.2Hz),22.47(t,J=4.3Hz).
19F NMR(376MHz,CDCl3)δ-97.90,-105.29.
实施例20 3,3-二氟-6-((4-甲氧基苯基)磺酰氨基)己基4-氟苯甲酸酯
在0℃下将6-氨基己-1-醇(2.0mmol,234mg)和三乙胺(2.2mmol,222mg)溶解在25mLDCM中。在5分钟内缓慢加入对甲氧基苯磺酰氯(2.2mmol,455mg)的DCM溶液(5mL)。滴加完成后,使混合物升温至室温并将溶液搅拌12h。用水(5mL)和饱和NaHCO3溶液(5mL)淬灭反应混合物。水相用10mL*3DCM萃取。合并的有机相用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化得到白色固体。在0℃下将得到的烷基醇(2.0mmol,574mg)和三乙胺(2.2mmol,222mg)溶解在25mLDCM中。在5分钟内缓慢加入对氟苯甲酰氯(2.2mmol,349mg)的DCM溶液(5mL)。滴加完成后,使混合物升温至室温并将溶液搅拌12h。用水(5mL)和饱和NaHCO3溶液(5mL)淬灭反应混合物。水相用10mL*3DCM萃取。合并的有机相用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化,得到白色固体的6-((4-甲氧基苯基)磺酰氨基)己基4-氟苯甲酸酯,收率97%。
在装有磁力搅拌的反应管中加入6-((4-甲氧基苯基)磺酰氨基)己基4-氟苯甲酸酯(81.9mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率67%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ8.05–7.99(m,2H),7.77(d,J=8.9Hz,2H),7.14–7.06(m,2H),6.95(d,J=8.9Hz,2H),5.02(s,1H),4.45(t,J=6.5Hz,2H),3.84(s,3H),2.96(q,J=6.3Hz,2H),2.27(tt,J=16.1,6.5Hz,2H),2.02–1.85(m,2H),1.76–1.63(m,2H).
13C NMR(101MHz,CDCl3)δ165.88(d,J=254.2Hz),165.38,162.97,132.17(d,J=9.4Hz),131.47,129.14,126.14(d,J=3.0Hz),123.58(t,J=241.6Hz),115.62(d,J=22.0Hz),114.33,58.95(t,J=5.8Hz),55.59,42.59,35.80(t,J=25.6Hz),33.81(t,J=25.2Hz),22.47(t,J=4.3Hz).
19F NMR(376MHz,CDCl3)δ-97.90,-105.29.
实施例21 3,3-二氟-6-((4-甲氧基苯基)磺酰氨基)己基4-氟苯甲酸酯
在0℃下将6-氨基己-1-醇(2.0mmol,234mg)和三乙胺(2.2mmol,222mg)溶解在25mLDCM中。在5分钟内缓慢加入对甲氧基苯磺酰氯(2.2mmol,455mg)的DCM溶液(5mL)。滴加完成后,使混合物升温至室温并将溶液搅拌12h。用水(5mL)和饱和NaHCO3溶液(5mL)淬灭反应混合物。水相用10mL*3DCM萃取。合并的有机相用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化得到白色固体。在0℃下将得到的烷基醇(2.0mmol,574mg)和三乙胺(2.2mmol,222mg)溶解在25mLDCM中。在5分钟内缓慢加入对氟苯甲酰氯(2.2mmol,349mg)的DCM溶液(5mL)。滴加完成后,使混合物升温至室温并将溶液搅拌12h。用水(5mL)和饱和NaHCO3溶液(5mL)淬灭反应混合物。水相用10mL*3DCM萃取。合并的有机相用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化,得到白色固体的6-((4-甲氧基苯基)磺酰氨基)己基4-氟苯甲酸酯,收率97%。
在装有磁力搅拌的反应管中加入6-((4-甲氧基苯基)磺酰氨基)己基4-氟苯甲酸酯(81.9mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(2.1mg,0.1mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率70%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ8.05–7.99(m,2H),7.77(d,J=8.9Hz,2H),7.14–7.06(m,2H),6.95(d,J=8.9Hz,2H),5.02(s,1H),4.45(t,J=6.5Hz,2H),3.84(s,3H),2.96(q,J=6.3Hz,2H),2.27(tt,J=16.1,6.5Hz,2H),2.02–1.85(m,2H),1.76–1.63(m,2H).
13C NMR(101MHz,CDCl3)δ165.88(d,J=254.2Hz),165.38,162.97,132.17(d,J=9.4Hz),131.47,129.14,126.14(d,J=3.0Hz),123.58(t,J=241.6Hz),115.62(d,J=22.0Hz),114.33,58.95(t,J=5.8Hz),55.59,42.59,35.80(t,J=25.6Hz),33.81(t,J=25.2Hz),22.47(t,J=4.3Hz).
19F NMR(376MHz,CDCl3)δ-97.90,-105.29.
实施例22 N-(6-(1,3-二氧代异吲哚啉-2-基)-4,4-二氟己基)-4-甲氧基苯磺酰胺
在25mL Schlenk反应管中,将邻苯二甲酰亚胺钾(5mmol,926mg)和1-氯-6-碘己烷(5.5mmol,1.3g)在氮气气氛下溶解在10mL无水DMF中。将反应混合物在室温下搅拌过夜。将反应混合物用100mL水稀释,并用10mL*3乙酸乙酯萃取。合并的有机相用饱和盐水洗涤并用无水Na2SO4干燥,减压浓缩。将粗产物通过色谱法纯化以得到呈无色油状液体。将得到的烷基氯(2.0mmol,531mg)、对甲氧基苯磺酰胺(4.0mmol,749mg)、碳酸钾(4.0mmol,553mg)和碘化钾(4.0mmol,332mg)加入装有8mL DMF的圆底烧瓶。然后将反应混合物加热至90℃并保持24h。冷却至室温后,将反应混合物用100mL水稀释并用10mL*3DCM萃取。合并的有机相用饱和盐水洗涤并用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化,得到白色固体的N-(6-(1,3-二氧代异吲哚啉-2-基)己基)-4-甲氧基苯磺酰胺,产率77%。
在装有磁力搅拌的反应管中加入N-(6-(1,3-二氧代异吲哚啉-2-基)己基)-4-甲氧基苯磺酰胺(83.3mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在0℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率29%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.84(dd,J=5.5,3.0Hz,2H),7.79(d,J=8.9Hz,2H),7.72(dd,J=5.5,3.0Hz,2H),6.97(d,J=8.9Hz,2H),4.68(s,1H),3.91–3.86(m,2H),3.85(s,3H),2.98(t,J=6.6Hz,2H),2.20(tt,J=16.2,7.3Hz,2H),2.03–1.82(m,2H),1.75–1.60(m,2H).
13C NMR(101MHz,CDCl3)δ167.98,162.95,134.07,132.02,131.58,129.19,123.64(t,J=241.5Hz),123.35,114.32,55.60,42.54,34.78(t,J=25.3Hz),33.27(t,J=25.1Hz),31.82(t,J=5.8Hz),22.46(t,J=4.3Hz).
19F NMR(376MHz,CDCl3)δ-98.95.
实施例23 3,3-二氟-6-((4-甲氧基苯基)磺酰氨基)己基(2S,5R)-3,3-二甲基-7-氧代-4-硫杂-1-氮杂双环[3.2.0]庚烷-2-羧酸酯4,4-二氧化物
在0℃下将6-氨基己-1-醇(2.0mmol,234mg)和三乙胺(2.2mmol,222mg)溶解在25mLDCM中。在5分钟内缓慢加入对甲氧基苯磺酰氯(2.2mmol,455mg)的DCM溶液(5mL)。滴加完成后,使混合物升温至室温并将溶液搅拌12h。用水(5mL)和饱和NaHCO3溶液(5mL)淬灭反应混合物。水相用10mL*3DCM萃取。合并的有机相用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化得到白色固体。将得到的烷基醇(1.2mmol,345mg),舒巴坦酸(1.0mmol,233mg)、和4-二甲氨基吡啶(0.1mmol,12mg)溶解在无水DCM(5mL)中的溶液,然后加入二环己基碳二亚胺(1.2mmol,248mg)。将反应混合物在室温下搅拌6h,然后减压浓缩。向残留物中加入冷的10mL乙酸乙酯,并滤出二环己基脲。减压浓缩溶液,粗产物通过色谱法纯化得到白色的6-((4-甲氧基苯基)磺酰氨基)己基(2S,5R)-3,3-二甲基-7-氧代-4-硫杂-1-氮杂双环[3.2.0]庚烷-2-羧酸酯4,4-二氧化物,收率85%。
在装有磁力搅拌的反应管中加入6-((4-甲氧基苯基)磺酰氨基)己基(2S,5R)-3,3-二甲基-7-氧代-4-硫杂-1-氮杂双环[3.2.0]庚烷-2-羧酸酯4,4-二氧化物(100.5mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在50℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率43%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.79(d,J=8.9Hz,2H),7.00(d,J=8.9Hz,2H),4.98(t,J=6.4Hz,1H),4.66(dd,J=4.4,2.0Hz,1H),4.47–4.32(m,3H),3.88(s,3H),3.58–3.40(m,2H),2.97(q,J=6.6Hz,2H),2.33–2.15(m,2H),2.03–1.86(m,2H),1.77–1.65(m,2H),1.61(s,3H),1.43(s,3H).
13C NMR(101MHz,CDCl3)δ171.07,166.88,162.98,131.39,129.14,123.32(t,J=241.8Hz),114.36,63.22,62.83,61.08,60.18(t,J=5.6Hz),55.64,42.48,38.25,35.48(t,J=25.7Hz),33.87(t,J=25.1Hz),22.39(t,J=4.3Hz),20.16,18.36.
19F NMR(376MHz,CDCl3)δ-98.37(dd,J=271.9,244.0Hz).
实施例24 3,3-二氟-6-((4-甲氧基苯基)磺酰氨基)己基(2S,5R)-3,3-二甲基-7-氧代-4-硫杂-1-氮杂双环[3.2.0]庚烷-2-羧酸酯4,4-二氧化物
在0℃下将6-氨基己-1-醇(2.0mmol,234mg)和三乙胺(2.2mmol,222mg)溶解在25mLDCM中。在5分钟内缓慢加入对甲氧基苯磺酰氯(2.2mmol,455mg)的DCM溶液(5mL)。滴加完成后,使混合物升温至室温并将溶液搅拌12h。用水(5mL)和饱和NaHCO3溶液(5mL)淬灭反应混合物。水相用10mL*3DCM萃取。合并的有机相用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化得到白色固体。将得到的烷基醇(1.2mmol,345mg),舒巴坦酸(1.0mmol,233mg)、和4-二甲氨基吡啶(0.1mmol,12mg)溶解在无水DCM(5mL)中的溶液,然后加入二环己基碳二亚胺(1.2mmol,248mg)。将反应混合物在室温下搅拌6h,然后减压浓缩。向残留物中加入冷的10mL乙酸乙酯,并滤出二环己基脲。减压浓缩溶液,粗产物通过色谱法纯化得到白色的6-((4-甲氧基苯基)磺酰氨基)己基(2S,5R)-3,3-二甲基-7-氧代-4-硫杂-1-氮杂双环[3.2.0]庚烷-2-羧酸酯4,4-二氧化物,收率85%。
在装有磁力搅拌的反应管中加入6-((4-甲氧基苯基)磺酰氨基)己基(2S,5R)-3,3-二甲基-7-氧代-4-硫杂-1-氮杂双环[3.2.0]庚烷-2-羧酸酯4,4-二氧化物(100.5mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率65%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.79(d,J=8.9Hz,2H),7.00(d,J=8.9Hz,2H),4.98(t,J=6.4Hz,1H),4.66(dd,J=4.4,2.0Hz,1H),4.47–4.32(m,3H),3.88(s,3H),3.58–3.40(m,2H),2.97(q,J=6.6Hz,2H),2.33–2.15(m,2H),2.03–1.86(m,2H),1.77–1.65(m,2H),1.61(s,3H),1.43(s,3H).
13C NMR(101MHz,CDCl3)δ171.07,166.88,162.98,131.39,129.14,123.32(t,J=241.8Hz),114.36,63.22,62.83,61.08,60.18(t,J=5.6Hz),55.64,42.48,38.25,35.48(t,J=25.7Hz),33.87(t,J=25.1Hz),22.39(t,J=4.3Hz),20.16,18.36.
19F NMR(376MHz,CDCl3)δ-98.37(dd,J=271.9,244.0Hz).
实施例25 3,3-二氟-6-((4-甲氧基苯基)磺酰氨基)己基(2S,5R)-3,3-二甲基-7-氧代-4-硫杂-1-氮杂双环[3.2.0]庚烷-2-羧酸酯4,4-二氧化物
在0℃下将6-氨基己-1-醇(2.0mmol,234mg)和三乙胺(2.2mmol,222mg)溶解在25mLDCM中。在5分钟内缓慢加入对甲氧基苯磺酰氯(2.2mmol,455mg)的DCM溶液(5mL)。滴加完成后,使混合物升温至室温并将溶液搅拌12h。用水(5mL)和饱和NaHCO3溶液(5mL)淬灭反应混合物。水相用10mL*3DCM萃取。合并的有机相用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化得到白色固体。将得到的烷基醇(1.2mmol,345mg),舒巴坦酸(1.0mmol,233mg)、和4-二甲氨基吡啶(0.1mmol,12mg)溶解在无水DCM(5mL)中的溶液,然后加入二环己基碳二亚胺(1.2mmol,248mg)。将反应混合物在室温下搅拌6h,然后减压浓缩。向残留物中加入冷的10mL乙酸乙酯,并滤出二环己基脲。减压浓缩溶液,粗产物通过色谱法纯化得到白色的6-((4-甲氧基苯基)磺酰氨基)己基(2S,5R)-3,3-二甲基-7-氧代-4-硫杂-1-氮杂双环[3.2.0]庚烷-2-羧酸酯4,4-二氧化物,收率85%。
在装有磁力搅拌的反应管中加入6-((4-甲氧基苯基)磺酰氨基)己基(2S,5R)-3,3-二甲基-7-氧代-4-硫杂-1-氮杂双环[3.2.0]庚烷-2-羧酸酯4,4-二氧化物(100.5mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在35℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率66%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.79(d,J=8.9Hz,2H),7.00(d,J=8.9Hz,2H),4.98(t,J=6.4Hz,1H),4.66(dd,J=4.4,2.0Hz,1H),4.47–4.32(m,3H),3.88(s,3H),3.58–3.40(m,2H),2.97(q,J=6.6Hz,2H),2.33–2.15(m,2H),2.03–1.86(m,2H),1.77–1.65(m,2H),1.61(s,3H),1.43(s,3H).
13C NMR(101MHz,CDCl3)δ171.07,166.88,162.98,131.39,129.14,123.32(t,J=241.8Hz),114.36,63.22,62.83,61.08,60.18(t,J=5.6Hz),55.64,42.48,38.25,35.48(t,J=25.7Hz),33.87(t,J=25.1Hz),22.39(t,J=4.3Hz),20.16,18.36.
19F NMR(376MHz,CDCl3)δ-98.37(dd,J=271.9,244.0Hz).
实施例26 N-(6-氯-4,4-二氟己基)-4-甲氧基苯磺酰胺
在0℃下将6-氨基己-1-醇(2.0mmol,234mg)和三乙胺(2.2mmol,222mg)溶解在25mLDCM中。在5分钟内缓慢加入对甲氧基苯磺酰氯(2.2mmol,455mg)的DCM溶液(5mL)。滴加完成后,使混合物升温至室温并将溶液搅拌12h。用水(5mL)和饱和NaHCO3溶液(5mL)淬灭反应混合物。水相用10mL*3DCM萃取。合并的有机相用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化得到白色固体。在氮气气氛下,向25mL Schlenk反应管中加入上步得到的烷基醇(2.0mmol,574mg)、三苯基膦(2.4mmol,629mg)、四丁基碘化铵(2.4mmol,886mg)和无水1,2-二氯乙烷(20mL)。将混合物加热回流反应0.5h,冷却至室温,通过减压浓缩除去溶剂。通过色谱法纯化残余物以得到白色固体N-(6-氯己基)-4-甲氧基苯磺酰胺,收率90%。
在装有磁力搅拌的反应管中加入N-(6-氯己基)-4-甲氧基苯磺酰胺(61.2mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应0.5h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率22%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.79(d,J=8.9Hz,2H),6.98(d,J=8.9Hz,2H),4.88(s,1H),3.86(s,3H),3.65–3.54(m,2H),2.97(q,J=6.4Hz,2H),2.27(tt,J=15.8,7.6Hz,2H),1.96–1.80(m,2H),1.72–1.62(m,2H).
13C NMR(101MHz,CDCl3)δ163.01,131.43,129.18,123.22(t,J=241.8Hz),114.36,55.63,42.52,39.83(t,J=25.6Hz),36.85(t,J=6.3Hz),33.67(t,J=25.1Hz),22.43(t,J=4.4Hz).
19F NMR(376MHz,CDCl3)δ-98.72.
实施例27 N-(6-溴-4,4-二氟己基)-4-甲氧基苯磺酰胺
在0℃下将6-氨基己-1-醇(2.0mmol,234mg)和三乙胺(2.2mmol,222mg)溶解在25mLDCM中。在5分钟内缓慢加入对甲氧基苯磺酰氯(2.2mmol,455mg)的DCM溶液(5mL)。滴加完成后,使混合物升温至室温并将溶液搅拌12h。用水(5mL)和饱和NaHCO3溶液(5mL)淬灭反应混合物。水相用10mL*3DCM萃取。合并的有机相用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化得到白色固体即为上了保护基的烷基醇;在0℃条件下,向含溶解有上步得到的含保护基的烷基醇(2.0mmol,574mg)的无水二氯甲烷(10mL)溶液中加入四溴化碳(2.0mmol,663mg)和三苯膦(2.0mmol,524mg),随后将混合物在室温下搅拌2h并在减压浓缩,通过色谱法纯化残余物,以得白色固体的N-(6-溴己基)-4-甲氧基苯磺酰胺,收率72%。
在装有磁力搅拌的反应管中加入N-(6-溴己基)-4-甲氧基苯磺酰胺(70.1mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应10h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率34%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.79(d,J=9.0Hz,2H),6.98(d,J=9.0Hz,2H),4.66(t,J=5.8Hz,1H),3.87(s,3H),3.45–3.38(m,2H),2.98(q,J=6.5Hz,2H),2.46–2.29(m,2H),1.95–1.79(m,2H),1.72–1.59(m,2H).
13C NMR(101MHz,CDCl3)δ163.02,131.47,129.18,123.40(t,J=243.2Hz),114.36,55.63,42.53,40.33(t,J=25.7Hz),33.55(t,J=25.1Hz),23.20(t,J=6.0Hz),22.45(t,J=4.4Hz).
19F NMR(376MHz,CDCl3)δ-99.24.
实施例28 N-(6-溴-4,4-二氟己基)-4-甲氧基苯磺酰胺
在0℃下将6-氨基己-1-醇(2.0mmol,234mg)和三乙胺(2.2mmol,222mg)溶解在25mLDCM中。在5分钟内缓慢加入对甲氧基苯磺酰氯(2.2mmol,455mg)的DCM溶液(5mL)。滴加完成后,使混合物升温至室温并将溶液搅拌12h。用水(5mL)和饱和NaHCO3溶液(5mL)淬灭反应混合物。水相用10mL*3DCM萃取。合并的有机相用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化得到白色固体,即为含保护基的烷基醇。在0℃条件下,向含溶解有上步得到的含保护基的烷基醇(2.0mmol,574mg)的无水二氯甲烷(10mL)溶液中加入四溴化碳(2.0mmol,663mg)和三苯膦(2.0mmol,524mg),随后将混合物在室温下搅拌2h并在减压浓缩,通过色谱法纯化残余物,以得白色固体的N-(6-溴己基)-4-甲氧基苯磺酰胺,收率72%。
在装有磁力搅拌的反应管中加入N-(6-溴己基)-4-甲氧基苯磺酰胺(70.1mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应1.5h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率52%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.79(d,J=9.0Hz,2H),6.98(d,J=9.0Hz,2H),4.66(t,J=5.8Hz,1H),3.87(s,3H),3.45–3.38(m,2H),2.98(q,J=6.5Hz,2H),2.46–2.29(m,2H),1.95–1.79(m,2H),1.72–1.59(m,2H).
13C NMR(101MHz,CDCl3)δ163.02,131.47,129.18,123.40(t,J=243.2Hz),114.36,55.63,42.53,40.33(t,J=25.7Hz),33.55(t,J=25.1Hz),23.20(t,J=6.0Hz),22.45(t,J=4.4Hz).
19F NMR(376MHz,CDCl3)δ-99.24.
实施例29 N-(6-溴-4,4-二氟己基)-4-甲氧基苯磺酰胺
在0℃下将6-氨基己-1-醇(2.0mmol,234mg)和三乙胺(2.2mmol,222mg)溶解在25mLDCM中。在5分钟内缓慢加入对甲氧基苯磺酰氯(2.2mmol,455mg)的DCM溶液(5mL)。滴加完成后,使混合物升温至室温并将溶液搅拌12h。用水(5mL)和饱和NaHCO3溶液(5mL)淬灭反应混合物。水相用10mL*3DCM萃取。合并的有机相用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化得到白色固体。向含溶解有上步得到的烷基醇(2.0mmol,574mg)的无水二氯甲烷(10mL)溶液中加入四溴化碳(2.0mmol,663mg)和三苯膦(2.0mmol,524mg)在0℃。将混合物在室温下搅拌2h并在减压下浓缩。通过色谱法纯化残余物,以得白色固体的N-(6-溴己基)-4-甲氧基苯磺酰胺,收率72%。
在装有磁力搅拌的反应管中加入N-(6-溴己基)-4-甲氧基苯磺酰胺(70.1mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应3.5h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率55%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.79(d,J=9.0Hz,2H),6.98(d,J=9.0Hz,2H),4.66(t,J=5.8Hz,1H),3.87(s,3H),3.45–3.38(m,2H),2.98(q,J=6.5Hz,2H),2.46–2.29(m,2H),1.95–1.79(m,2H),1.72–1.59(m,2H).
13C NMR(101MHz,CDCl3)δ163.02,131.47,129.18,123.40(t,J=243.2Hz),114.36,55.63,42.53,40.33(t,J=25.7Hz),33.55(t,J=25.1Hz),23.20(t,J=6.0Hz),22.45(t,J=4.4Hz).
19F NMR(376MHz,CDCl3)δ-99.24.
实施例30 3,3-二氟-6-(4-甲氧基苯基)磺酰胺基)己基-2-(4-(4-氯苯甲酰基)苯氧基)-2-甲基丙酸酯
在0℃下将6-氨基己-1-醇(2.0mmol,234mg)和三乙胺(2.2mmol,222mg)溶解在25mLDCM中。在5分钟内缓慢加入对甲氧基苯磺酰氯(2.2mmol,455mg)的DCM溶液(5mL)。滴加完成后,使混合物升温至室温并将溶液搅拌12h。用水(5mL)和饱和NaHCO3溶液(5mL)淬灭反应混合物。水相用10mL*3DCM萃取。合并的有机相用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化得到白色固体烷基醇。将得到的烷基醇(1.2mmol,345mg),非诺贝特酸(1.0mmol,319mg)、和4-二甲氨基吡啶(0.1mmol,12mg)溶解在无水DCM(5mL)中的溶液,然后加入二环己基碳二亚胺(1.2mmol,248mg)。将反应混合物在室温下搅拌6h,然后减压浓缩。向残留物中加入冷的10mL乙酸乙酯,并滤出二环己基脲。减压浓缩溶液,粗产物通过色谱法纯化得到白色的6-(4-(4-甲氧基苯基)磺酰胺基)2-(4-(4-氯苯甲酰基)苯氧基)-2-甲基丙酸己酯,收率82%。
在装有磁力搅拌的反应管中加入6-(4-(4-甲氧基苯基)磺酰胺基)2-(4-(4-氯苯甲酰基)苯氧基)-2-甲基丙酸己酯(117.6mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率79%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.78(d,J=8.4Hz,2H),7.74–7.66(m,4H),7.44(d,J=8.1Hz,2H),6.97(d,J=8.4Hz,2H),6.84(d,J=8.3Hz,2H),4.85(s,1H),4.32(t,J=6.6Hz,2H),3.86(s,3H),2.91(q,J=5.9Hz,2H),2.09(tt,J=15.0,6.3Hz,2H),1.86–1.73(m,2H),1.67(s,6H),1.63–1.52(m,2H).
13C NMR(101MHz,CDCl3)δ194.48,173.45,162.92,159.56,138.59,136.18,132.05,131.43,131.28,130.53,129.18,128.61,123.32(t,J=241.6Hz),117.24,114.30,79.38(t,J=5.8Hz),59.53(t,J=5.8Hz),55.64,42.54,35.42(t,J=25.8Hz),33.68(t,J=25.1Hz),25.37,22.41(t,J=4.0Hz).
19F NMR(376MHz,CDCl3)δ-98.02.
实施例31(1S,2R,5S)-2-异丙基-5-甲基环己基-4,4-二氟-7-(4-甲氧基苯基)磺酰胺基)庚酸酯
在圆底烧瓶中加入7-氨基庚酸盐酸盐(5mmol,908mg)和15mL水并于0℃搅拌,缓慢加入10mL 1M NaOH的水溶液,添加完毕后搅拌10分钟。在上一步的反应液中加入三乙胺(5.5mmol,557mg),缓慢滴加溶解有对甲基苯磺酰氯(5.25mmol,1.085g)的THF(5mL)溶液,添加完毕后升温至室温搅拌反应12个h。反应混合物用20mL乙醚萃取,水相备用,然后乙醚层用20mL 2M NaOH洗涤,弃去乙醚层。合并水相并在0℃下用1M HCl水溶液调节pH至2。最后用30mL*3乙酸乙酯萃取水相,有机相依次用饱和盐水和无水Na2SO4干燥,减压浓缩,得到白色固体烷基酸。将得到的烷基酸(1.0mmol,301mg),薄荷醇(1.0mmol,156mg)、和4-二甲氨基吡啶(0.1mmol,12mg)溶解在无水DCM(5mL)中的溶液,然后加入二环己基碳二亚胺(1.2mmol,248mg)。将反应混合物在室温下搅拌6h,然后减压浓缩。向残留物中加入冷的10mL乙酸乙酯,并滤出二环己基脲。减压浓缩溶液,粗产物通过色谱法纯化得到白色的(1S,2R,5S)-2-异丙基-5-甲基环己基7-(4-甲氧基苯基)磺酰胺基)庚酸酯,收率67%。
在装有磁力搅拌的反应管中加入(1S,2R,5S)-2-异丙基-5-甲基环己基7-(4-甲氧基苯基)磺酰胺基)庚酸酯(90.7mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率75%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.79(d,J=8.2Hz,2H),6.98(d,J=7.9Hz,2H),4.75–4.55(m,2H),3.87(s,3H),2.97(s,2H),2.46(t,J=7.5Hz,2H),2.12(tt,J=15.8,7.5Hz,2H),2.00–1.92(m,1H),1.92–1.76(m,3H),1.73–1.61(m,4H),1.54–1.41(m,1H),1.36(t,J=11.2Hz,1H),1.08–0.82(m,9H),0.74(d,J=6.7Hz,3H).
13C NMR(101MHz,CDCl3)δ171.93,162.96,131.36,129.19,123.92(t,J=241.2Hz),114.33,74.68,55.64,46.95,42.61,40.82,34.20,33.60(t,J=25.4Hz),31.85(t,J=25.7Hz),31.37,27.43(t,J=4.5Hz),26.26,23.40,22.51(t,J=4.1Hz),22.02,20.76,16.30.
19F NMR(376MHz,CDCl3)δ-100.32.
实施例32(S)-2-((S)-5,5-二氟-2-((4-甲氧基苯基)磺酰氨基)己酰氨基)己酸甲酯
将L-正亮氨酸(10mmol,1.3g)加入100mL甲醇中并在0℃下冷却。加入二氯亚砜(30mmol,3.6g),使混合物升温至室温并将溶液搅拌12h。减压浓缩溶液以获得粗胺盐酸盐。在0℃下将粗胺盐酸盐和三乙胺(30mmol,0.3g)溶解在50mLDCM中。在5分钟内缓慢加入对甲氧基苯磺酰氯(10mmol,2.1g)的DCM溶液(20mL)。添加完成后,使混合物升温至室温并将溶液搅拌12h。用水(10mL)和1.0M HCl(10mL)淬灭反应混合物。水相用20mL*3DCM萃取,合并的有机相用无水Na2SO4干燥,减压浓缩。粗产物通过色谱法纯化,得到白色固体的(S)-2-((S)-2-((4-甲氧基苯基)磺酰氨基)己酰氨基)己酸甲酯,收率8%。
在装有磁力搅拌的反应管中加入(S)-2-((S)-2-((4-甲氧基苯基)磺酰氨基)己酰氨基)己酸甲酯(85.7mg,0.2mmol),Selectfluor(106.3mg,0.6mmol),蒽醌(0.4mg,0.002mmol),再加入总体积为4ml的乙腈与2,2,2-三氟乙醇比例为2:1的混合溶剂,氮气置换三次后,将反应体系置于功率为25W*2的蓝光下照射,在25℃下搅拌反应2h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到目标化合物,收率63%。
产物核磁共振谱表征数据如下:
1H NMR(400MHz,CDCl3)δ7.77(d,J=8.3Hz,2H),6.94(d,J=8.3Hz,2H),6.35(d,J=6.1Hz,1H),5.56(d,J=8.7Hz,1H),4.35(q,J=7.0Hz,1H),3.84(s,3H),3.82–3.74(m,1H),3.71(s,3H),2.01–1.61(m,6H),1.55(t,J=18.5Hz,3H),1.28–1.20(m,2H),1.16–1.01(m,2H),0.86(t,J=7.3Hz,3H).
13C NMR(101MHz,CDCl3)δ172.39,170.10,163.13,131.14,129.40,123.83(t,J=238.3Hz),114.28,55.76,55.59,52.46,52.45,33.42(t,J=25.6Hz),31.76,27.21,26.88(t,J=4.2Hz),23.55(t,J=27.8Hz),22.13,13.75.
19F NMR(376MHz,CDCl3)δ-91.34(dd,J=257.2,238.4Hz).
以上实施仅用以说明本发明的技术方案而非限制本发明,尽管参照较佳实施例对本发明进行了详细说明,本领域的普通技术人员应当理解,可以对发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的精神和范围,其均应涵盖在本发明的权利要求范围内。
Claims (10)
2.根据权利要求1所述的一种由脂肪胺合成二氟烷基类化合物的方法,其特征在于氟化试剂为Selectfluor(1-氯甲基-4-氟-1,4-二氮杂双环[2.2.2]辛烷二(四氟硼酸)盐)或NFSI(N-氟代双苯磺酰胺)。
3.根据权利要求1所述的一种由脂肪胺合成二氟烷基类化合物的方法,其特征在于催化剂为蒽醌或蒽醌衍生物。
4.根据权利要求1所述的一种由脂肪胺合成二氟烷基类化合物的方法,其特征在于光源为白光、蓝光或紫光。
5.根据权利要求1所述的一种由脂肪胺合成二氟烷基类化合物的方法,其特征在于式(Ⅰ)所示的脂肪胺、氟化试剂、催化剂的物质的量比为1:2.0~5.0:0.001~0.1,优选摩尔比为1:2.5~3.5:0.01~0.05。
6.根据权利要求1所述的一种由脂肪胺合成二氟烷基类化合物的方法,其特征在于反应温度为0-50℃,优选为25-35℃。
7.根据权利要求1所述的一种由脂肪胺合成二氟烷基类化合物的方法,其特征在于反应时间为0.5~10h,优选为1.5-3.5h。
8.根据权利要求1-7任一项所述的一种由脂肪胺合成二氟烷基类化合物的方法,其特征在于溶剂为A溶剂与B溶剂的混合溶剂,A溶剂选自2,2,2-三氟乙醇或1,1,1,3,3,3-六氟-2-丙醇,B溶剂选自乙腈、乙酸乙酯、二甲基亚砜或二氯甲烷中的一种,A溶剂与B溶剂的投料体积比0.1~1.0:1,优选为0.4-0.6:1。
9.根据权利要求1-7任一项所述的一种由脂肪胺合成二氟烷基类化合物的方法,其特征在于分离、提纯的具体处理过程为:反应液减压浓缩后经色谱柱分离纯化,得到式(Ⅱ)所示的二氟烷基化合物。
10.根据权利要求1-7任一项所述的一种由脂肪胺合成二氟烷基类化合物的方法,其特征在于所述方法为:在装有磁力搅拌的反应管中加入式(Ⅰ)所示的脂肪胺、氟化试剂、催化剂和反应溶剂,氮气置换后,将反应体系置于光源照射下,于0-50℃下搅拌反应0.5~10h,反应结束后反应液减压浓缩经色谱柱分离纯化,得到式(Ⅱ)所示的目标化合物二氟烷基类化合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310251612.7A CN116375611A (zh) | 2023-03-16 | 2023-03-16 | 一种由脂肪胺合成二氟烷基类化合物的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310251612.7A CN116375611A (zh) | 2023-03-16 | 2023-03-16 | 一种由脂肪胺合成二氟烷基类化合物的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116375611A true CN116375611A (zh) | 2023-07-04 |
Family
ID=86964843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310251612.7A Pending CN116375611A (zh) | 2023-03-16 | 2023-03-16 | 一种由脂肪胺合成二氟烷基类化合物的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116375611A (zh) |
-
2023
- 2023-03-16 CN CN202310251612.7A patent/CN116375611A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yajima et al. | Photoinduced addition and addition–elimination reactions of perfluoroalkyl iodides to electron-deficient olefins | |
Avenoza et al. | Enantioselective synthesis of (S)-and (R)-α-methylserines: application to the synthesis of (S)-and (R)-N-Boc-N, O-isopropylidene-α-methylserinals | |
CN114591194B (zh) | 一种对位官能团化芳胺化合物及其合成方法 | |
WO2015106624A1 (zh) | 2,4(1h,3h)-嘧啶二酮衍生物及其制备方法 | |
CN109879731B (zh) | 一类二芳基甲烷卤代烯烃衍生物及制备方法 | |
ES2394973T3 (es) | Procedimiento para la preparación estereoselectiva de (-)-halofenato e intermedios para el mismo | |
CN1243725C (zh) | 制备腈类化合物的方法 | |
CN116375611A (zh) | 一种由脂肪胺合成二氟烷基类化合物的方法 | |
CN114573512B (zh) | 一种合成c2-二氟烷基苯并咪唑衍生物的方法 | |
JP2011057665A (ja) | 光学活性な1−アミノ−2−ビニルシクロプロパンカルボン酸エステルの製造方法 | |
CN111875523B (zh) | α-氟乙烯基硫醚衍生物的合成方法 | |
JP6226363B2 (ja) | ビス−ボロンジピロメテン系色素 | |
KR20060070485A (ko) | 프로키랄 및 메소 사이클릭 무수물의 촉매적 비대칭탈대칭화 | |
JP2012020952A (ja) | ヨードニウム化合物、その製造方法、及び官能基化スピロ環状化合物とその製造方法 | |
CN1733714A (zh) | 富马酸伊布利特的合成方法 | |
JP3979743B2 (ja) | 光学活性なビニルホスフィンオキシドの製造方法 | |
Kamińska et al. | Application of sulfonyl chlorides and chiral amines in the efficient synthesis of nonracemic sulfinamides | |
JP2014151285A (ja) | 新規光学活性イミダゾリン−リン酸触媒とその誘導体 | |
CN111777530B (zh) | 一种催化三氟甲基酮不对称Henry反应的方法 | |
KR100976966B1 (ko) | 비스(디페닐비닐)아렌 화합물 | |
Lai et al. | A One-Pot and Efficient Preparation of (S)-Benzyl 4-Hydroxy-2-Pentynoate from (S)-n-Butyn-2-Ol Using an Unusual Lithiation with n-BuLi and a Catalytic Amount of Hexamethyldisilazane | |
CN116332712A (zh) | 一种手性硫醇和氘水促进的烯烃的不对称氘官能团化方法 | |
CN1560029A (zh) | 取代顺式1,2-二氰乙烯及其合成方法 | |
Yuan et al. | Facile and Efficient Asymmetric Synthesis of α‐Aminoalkylphosphonic Acids | |
JP4374088B2 (ja) | 新規な4,4−ジフルオロベンゾアゼピンケタール誘導体、およびそれを経由する4,4−ジフルオロベンゾアゼピン−5−オン誘導体の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |